Peptide RegisterUK

Independent UK reference

What these drugs actually are.

The information already exists, in regulatory documents, trial papers and the BNF. It is just scattered and hard to read. Every entry here pulls it into one record, in the same order, and links back to the primary source.

  • Nothing sold
  • No doses or protocols
  • No affiliate links
  • No advertising
Record 01

Semaglutide

GLP-1 receptor agonist
MHRA licensed Prescription only Evidence: human RCT

Peptide sequence, one-letter notation

H·Aib·EGTFTSDVSSYLEGQAAK·EFIAWLVRGRG

Compound class

A 31-amino-acid analogue of human GLP-1, a hormone released by the gut after eating. Modified so it lasts about a week in the body rather than minutes.

Licensed for

Type 2 diabetes and weight management, under separate authorisations with separate brands and separate criteria. Which is why Ozempic and Wegovy are not interchangeable.

How it works

Binds the GLP-1 receptor. More insulin when glucose is high, slower stomach emptying, and reduced appetite signalling in the brain.

Sources
Record checked 25 July 2026 Read the full record

The register

Every compound, the same six sections

UK status comes first, because it is the thing most often misrepresented elsewhere. Licensed medicine, unlicensed, and research use only are three completely different legal and safety positions.

CompoundClassUK statusEvidence
SemaglutideOzempic, Wegovy, Rybelsus GLP-1 receptor agonist MHRA licensed Human RCT, phase 3
TirzepatideMounjaro Dual GIP and GLP-1 receptor agonist MHRA licensed Human RCT, phase 3
LiraglutideSaxenda, Victoza GLP-1 receptor agonist MHRA licensed Human RCT, phase 3
DulaglutideTrulicity GLP-1 receptor agonist MHRA licensed Human RCT, phase 3
ExenatideByetta and Bydureon. Availability has reduced; check current UK supply GLP-1 receptor agonist MHRA licensed Human RCT, phase 3
SomatropinMultiple brands, including Genotropin, Norditropin, Humatrope Recombinant human growth hormone Licensed, and a Class C controlled drug Human RCT for licensed uses
OrforglipronFoundayo in the United States. No UK brand name yet Non-peptide GLP-1 receptor agonist Not licensed in the UK Human RCT, phase 3
RetatrutideNo brand name. Development code LY3437943 Triple receptor agonist Not licensed anywhere Phase 3 ongoing
CagriSemaNo brand name. A combination of cagrilintide and semaglutide Amylin analogue plus GLP-1 receptor agonist Not licensed anywhere Phase 3 reported, no approval
CagrilintideNo brand name. The amylin component of CagriSema Long-acting amylin analogue Not licensed anywhere Human RCT, phase 3 as part of a combination
SurvodutideNo brand name. Development code BI 456906 Dual GLP-1 and glucagon receptor agonist Not licensed anywhere Phase 3 ongoing
MazdutideXinermei in China. Development codes IBI362 and LY3305677 Dual GLP-1 and glucagon receptor agonist Not licensed in the UK Human RCT, phase 3
TesamorelinEgrifta GHRH analogue Not licensed in the UK Human RCT for its licensed indication
AfamelanotideScenesse Melanocortin receptor agonist Licensed, but not for anything cosmetic Human RCT for its licensed indication
PT-141Bremelanotide. Marketed as Vyleesi in the United States Melanocortin receptor agonist Not licensed in the UK Human RCT for its licensed indication
Thymosin alpha-1Zadaxin in countries where it is licensed. Also written Ta1 Immunomodulatory peptide Not licensed in the UK Human RCT for its licensed indications
SemaxNo UK brand. Approved as a medicine in Russia Synthetic ACTH fragment analogue Unlicensed in the UK Russian clinical use, limited Western trial data
SelankNo UK brand. Approved as a medicine in Russia Synthetic tuftsin analogue Unlicensed in the UK Russian clinical use, limited Western trial data
SermorelinFormerly Geref, discontinued. No current UK brand GHRH analogue Unlicensed in the UK Human RCT, withdrawn from market
SS-31Elamipretide. Also written MTP-131 or Bendavia Mitochondria-targeted tetrapeptide Not licensed in the UK Human RCT, no approval
GHK-CuCopper peptide. Also written GHK-copper Copper tripeptide Cosmetic ingredient, not a medicine Limited early human studies
BPC-157Also written BPC 157, Bepecin, PL 14736 Synthetic pentadecapeptide Unlicensed medicine Animal studies, almost no human data
TB-500Related to thymosin beta-4, often conflated with it Synthetic peptide fragment Unlicensed medicine Animal studies, no human trials
KPVNo brand name. Sometimes written Lys-Pro-Val Tripeptide, fragment of alpha-MSH Unlicensed medicine No human trials
MOTS-cNo brand name. Sold as MOTS-c free base or MOTS-c acetate Mitochondrial-derived peptide Unlicensed medicine No human trials of the peptide itself
EpitalonAlso written Epithalon or Epithalamin Synthetic tetrapeptide Unlicensed medicine Cohort studies from one research group. No modern controlled trials.
EmideltideAlso called DSIP Delta sleep-inducing peptide Unlicensed medicine Human trials exist and contradict each other
CJC-1295Also sold as Mod GRF 1-29 or CJC-1295 no-DAC, which is a related but shorter-acting compound GHRH analogue Unlicensed medicine No human trials supporting marketed claims
IpamorelinNo brand name. Sold as a research chemical, usually blended with CJC-1295 Growth hormone secretagogue Unlicensed medicine Abandoned in development, no supporting human trials
HexarelinNo brand name. Sometimes written Examorelin Growth hormone releasing peptide Unlicensed medicine Early human studies, never approved
IGF-1 LR3Long R3 IGF-1. Related compounds sold as IGF-1 DES and PEG-MGF Modified insulin-like growth factor 1 Unlicensed medicine No human trials of the modified analogue
ACE-031No brand name. Also written ACVR2B-Fc Activin receptor fusion protein Unlicensed. Trials halted on safety. Human trials halted on safety grounds
AOD-9604Also written hGH 176-191 or hGH fragment 176-191 Growth hormone fragment Unlicensed medicine Human trials did not support the claims
MK-677Ibutamoren, ibutamoren mesylate, sometimes sold as Nutrobal Growth hormone secretagogue, non-peptide Unlicensed medicine Human trials exist, no approval
Melanotan IIMT-II, sold as tanning injections and nasal sprays Synthetic melanocortin receptor agonist Unlicensed medicine Limited early human studies

See the full register

Start here

Three things worth reading first

Foundations

What a peptide actually is

Insulin is one. So is Mounjaro. So is the powder sold in an unlabelled vial. The word covers all three, which is why it gets used so loosely.

Regulation

Licensed, unlicensed, research use only

Three labels that decide whether anything has been checked. The phrase not for human consumption on a vial is a legal position, not a quality statement.

Method

How to read a claim

Who ran the study, how many people, what it measured, and who paid. Most figures circulating online answer a narrower question than the claim suggests.

Practice

Peptide stacks, and the Wolverine stack

Two compounds with no human evidence do not add up to evidence. Combining them doubles every unknown and every supply risk, and the names are marketing.

Method

How a record gets built

  1. Start at the regulatorLicensing status and approved indications from the MHRA and the SPC, never from a secondary write-up.
  2. Add the clinical referenceMechanism, cautions and interactions from the BNF. Funding criteria from NICE.
  3. Trace every numberEach reported effect tied to the named trial it came from, with the funder stated.
  4. State what is missingWhere there is no human data, the record says so plainly instead of filling the gap.

Sources used

Where this comes from

  • MHRALicensing, safety alerts, Yellow Card
  • electronic medicines compendiumSummaries of Product Characteristics
  • BNFClinical monographs
  • NICETechnology appraisals
  • NHS EnglandAccess pathways and patient guidance
  • PubMed and CochraneTrials and systematic reviews
  • WADAProhibited list for athletes

See the full source list